Quest Diagnostics Incorporated (DGX) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Stability ⢠Strong Cash Flow ⢠Elevated Leverage DGX combines stable margins, strong cash conversion, and solid returns, but elevated leverage, thin liquidity, and a premium valuation mean the stock depends on continued earnings durability.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠$200 hold ⢠Near resistance Support Level: $196-$197 Resistance Level: $204-$205 Over the last month, DGX has maintained a constructive uptrend above $200, but price is now consolidating just below $205 and needs a clean breakout to extend higher.
Sentiment & News
Key News Insights: ⢠Valuation Upside ⢠Dividend Support ⢠Reimbursement Risk Quest Diagnostics is drawing bullish valuation and earnings upgrades on value, AI/diagnostics growth, and dividend support, but debt, reimbursement risks, and recent post-earnings weakness temper the outlook.
AI Summary
DGX has shifted from a defensive lab stock to a credible earnings-compounder thanks to 9% organic growth, raised guidance, and specialty-test adoption, but with valuation already near low-20s earnings and leverage still elevated, the stock's upside depends on continued EPS beats and a clean break above the $204â205 resistance rather than any major rerating.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |